CN1062018C - Detecting technique for human haemoglobin (globin) a* gene and gene a* - Google Patents
Detecting technique for human haemoglobin (globin) a* gene and gene a* Download PDFInfo
- Publication number
- CN1062018C CN1062018C CN92108379A CN92108379A CN1062018C CN 1062018 C CN1062018 C CN 1062018C CN 92108379 A CN92108379 A CN 92108379A CN 92108379 A CN92108379 A CN 92108379A CN 1062018 C CN1062018 C CN 1062018C
- Authority
- CN
- China
- Prior art keywords
- gene
- amplification
- genonema
- human hemoglobin
- electrophoresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 102000018146 globin Human genes 0.000 title abstract description 18
- 108060003196 globin Proteins 0.000 title abstract description 18
- 238000000034 method Methods 0.000 title description 9
- 238000001962 electrophoresis Methods 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 23
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 23
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 230000002068 genetic effect Effects 0.000 claims abstract description 3
- 101150087698 alpha gene Proteins 0.000 claims description 23
- 230000004544 DNA amplification Effects 0.000 claims description 5
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims description 4
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims 3
- -1 Methane amide Chemical class 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 238000012217 deletion Methods 0.000 abstract description 15
- 230000037430 deletion Effects 0.000 abstract description 15
- 230000003321 amplification Effects 0.000 abstract description 14
- 238000003205 genotyping method Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000010339 medical test Methods 0.000 abstract 1
- 201000006288 alpha thalassemia Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000012925 Hemoglobin H disease Diseases 0.000 description 5
- 238000012224 gene deletion Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
一种遗传检测方法,利用DNA聚合酶链反应(PCR)技术,对人血红蛋白(珠蛋白)α1基因和α2基因缺失进行基因分型检测。本发明设计了三对排列顺序明确的扩增引物αp1和αp3,αp1和αp2,βp1和βp2,它们分别扩增Hbα1基因278bp、Hbα2基因片段603bp、Hbβ基因片段400bp;用扩增反应配套的实验技术即扩增反应的试剂体系及其反应程序进行扩增反应,产物用电泳方法检测,可以准确判断受检的人血红蛋白(珠蛋白)α1基因和α2基因缺失α基因的个数。对科学研究、医学检测都有重要意义。本发明检测灵敏、准确、操作简便、价格低廉。A genetic detection method, which uses DNA polymerase chain reaction (PCR) technology to carry out genotyping detection for the deletion of human hemoglobin (globin) α 1 gene and α 2 gene. The present invention designs three pairs of amplification primers αp 1 and αp 3 , αp 1 and αp 2 , βp 1 and βp 2 with a clear arrangement order, which respectively amplify Hbα 1 gene 278bp, Hbα 2 gene fragment 603bp, and Hbβ gene fragment 400bp Carry out the amplification reaction with the matching experimental technique of the amplification reaction, i.e. the reagent system of the amplification reaction and its reaction program, and the product is detected by electrophoresis, which can accurately determine the tested human hemoglobin (globin) α 1 gene and α 2 gene Number of missing α genes. It is of great significance to scientific research and medical testing. The invention is sensitive, accurate, easy to operate and low in price.
Description
本发明属遗传检测领域,是用DNA聚合酶链反应(PCR)方法对人血红蛋白(珠蛋白)α1基因和α2基因检测的技术。The invention belongs to the field of genetic detection, and is a technique for detecting human hemoglobin (globin) α1 gene and α2 gene by using a DNA polymerase chain reaction (PCR) method.
编码血红蛋白(珠蛋白)的α1基因或α2基因的缺失会引起α-地中海贫血症(简称地贫)。它在我国是一种常见病,发病率为2.64%,广西的一些地区竟高达14.95%以上,目前尚无有效的根治方法,重症患者需常年输血,不仅本人十分痛苦,对家庭和社会也带来沉重的负担。Loss of the α1 or α2 gene encoding hemoglobin (globin) causes α-thalassemia (thalassemia for short). It is a common disease in my country, with an incidence rate of 2.64%, and it is as high as 14.95% in some areas of Guangxi. At present, there is no effective cure method, and severe patients need blood transfusions all year round. come a heavy burden.
α-地贫除少数是由α-基因的点突变引起外,多数是由α-基因的缺失所引起的。α-基因族有2个序列极为相似的α1和α1基因,二者之间只有7个核苷酸序列上的差异,它们在功能上是相同的,都编码α-珠蛋白分子,这二个基因的缺失或部分缺失,都会减少α-珠蛋白的合成。在正常人基因组中存在2个α1等位基因和2个α2等位基因。一般缺失一个α基因的患者表现为α-地贫2,贫血症状很轻或看不出症状;缺失2个α基因的患者表现为α-地贫1,贫血症状较重;缺失3个α基因的患者表现为HbH病,贫血症状严重,需常年输血;缺4个α基因的胎儿表现为Bart’s水肿,不能成活。α-thalassemia is mostly caused by the deletion of α-gene except for a few caused by point mutation of α-gene. There are two α1 and α1 genes with very similar sequences in the α-gene family. There are only 7 nucleotide sequence differences between the two. They are functionally identical, and both encode α-globin molecules. Deletion or partial deletion of both genes reduces α-globin synthesis. There are 2 α1 alleles and 2 α2 alleles in the normal human genome. Generally, patients who lack one α gene manifest as α-thalassemia 2, with mild or no symptoms of anemia; patients who lack 2 α genes exhibit α-thalassemia 1, with severe symptoms of anemia; those who lack 3 α genes The patient showed HbH disease, severe symptoms of anemia, and needed blood transfusion all year round; the fetus lacking 4 α genes showed Bart's edema and could not survive.
目前应用红细胞形态观察、血红蛋白电泳分析对人血红蛋白(珠蛋白)α1基因和α2基因的缺失进行分型检测,也可用限制性内切酶和α基因探针杂交等方法对α基因缺失情况进行研究,这些方法或则操作技术复杂,或则难于掌握客观标准。1987年以来,普遍采用设计在α基因族ψα1(α1假基因)基因内的一对引物对人血红蛋白(珠蛋白)α1基因或α2基因的缺失进行PCR(多聚酶链式反应Polymerase chain Reaction)扩增,如果α基因族包括α1和α2基因在内的大片段缺失时,可获得正确的检测结果;如果缺失仅为α1和α2基因或者是α1或α2基因而不包括ψα1时,则获得假阴性结果;如果缺失的仅为ψα1基因而α1和α2基因或者α1或α2基因并不缺失,则获得假阳性结果。所以这种PCR检测方法具有很大的局限性,况且中国的α-地贫患者多为α1和α2基因或者是α1或α2基因缺失,应用此法易于导致检测错误。At present, red blood cell morphology observation and hemoglobin electrophoresis analysis are used to detect the deletion of human hemoglobin (globin) α 1 gene and α 2 gene. Methods such as restriction endonuclease and α gene probe hybridization can also be used to detect the α gene deletion. For research, these methods are either technically complex or difficult to grasp objective standards. Since 1987, a pair of primers designed in the α gene family ψα 1 (α 1 pseudogene) gene has been generally used to carry out PCR (Polymerase chain reaction Polymerase chain reaction) for the deletion of human hemoglobin (globin) α 1 gene or α 2 gene Reaction) amplification, if a large fragment of the α gene family including α 1 and α 2 genes is deleted, the correct detection result can be obtained; if the deletion is only α 1 and α 2 genes or α 1 or α 2 genes False-negative results were obtained when ψα1 was not included; false-positive results were obtained if only the ψα1 gene was deleted and the α1 and α2 genes or α1 or α2 genes were not deleted. Therefore, this PCR detection method has great limitations. Moreover, most of the α-thalassemia patients in China have α1 and α2 genes or α1 or α2 gene deletions, and the application of this method may easily lead to detection errors.
本发明的目的是建立一种操作简单、方法简便、检测标准明确无误的人血红蛋白(珠蛋白)α1基因和α2基因的PCR基因分型检测技术。The purpose of the present invention is to establish a PCR genotyping detection technology of human hemoglobin (globin) α1 gene and α2 gene with simple operation, convenient method and unmistakable detection standard.
本发明用PCR扩增技术,主要有引物含成、基因扩增、显示检测主要步骤。发明设计了五种核苷酸引物,它们是:The invention uses the PCR amplification technology, mainly including the main steps of primer formation, gene amplification and display detection. Invention designed five nucleotide primers, which are:
αp1:5′d(CGG CTC TGC CCA GGT TAA GG)αp 1 : 5′d(CGG CTC TGC CCA GGT TAA GG)
αp1:5′d(CCT TGG TCT GAG ACA GGT AAA CA)αp 1 : 5′d(CCT TGG TCT GAG ACA GGT AAA CA)
αp1:5′d(AGT GGG GCC GAG GGC CCA G)αp 1 : 5′d(AGT GGG GCC GAG GGC CCA G)
βp1:5′d(AAG GAG ACC AAT AGA AAC TGG GC)βp 1 : 5′d(AAG GAG ACC AAT AGA AAC TGG GC)
βp1:5′d(TCT CCC CTT CCT ATG ACA TGA AC)βp 1 : 5′d(TCT CCC CTT CCT ATG ACA TGA AC)
其中αp1和αp2引物扩增Hbα1基因片断278bP,αp1和αp2扩增Hbα:基因片段603bp,βp1和βp2扩增Hbβ基因片段400bP。五种引物分别形成三对,扩增的片段具有明显的特征。Among them, αp 1 and αp 2 primers amplify Hbα 1 gene fragment 278bP, αp 1 and αp 2 amplify Hbα: gene fragment 603bp, βp 1 and βp 2 amplify Hbβ gene fragment 400bP. The five primers formed three pairs respectively, and the amplified fragments had obvious characteristics.
引物αp1、αp2、αp3、βp1、βp2按上述的核苷酸排列顺序,可以用化学方法合成。278bp、603bp、400bp的DNA片段可以用电泳法检测。如用普通的琼脂糖凝胶电泳分离DNA片段后用溴乙锭染色,在紫外光照射下的红色荧光来检测。The primers αp 1 , αp 2 , αp 3 , βp 1 , and βp 2 can be synthesized by chemical methods according to the above nucleotide sequence. 278bp, 603bp, 400bp DNA fragments can be detected by electrophoresis. For example, the DNA fragments are separated by ordinary agarose gel electrophoresis and stained with ethidium bromide, and detected by red fluorescence under ultraviolet light.
基因扩增的试剂体系是可以在30-100μl的反应体系中有10-50mM的Tris-HCl(PH=8.1-8.5),50mM的KCl,0.5-3.0mM的NgCl2,10-25mM的(NH4)2SO4,明胶200μg/ml,4-8%的甲酶胺,dNTP(A·G·C·T)各200-300μM,1-1.5U的耐热DNA聚含酶,0.25-0.5μM的αp1,0.125-0.25μM,的αp1,0.125-0.25μM的αp1,0.125-0.25μM的βp1,0.125-0.25μM的βp1。The reagent system for gene amplification can contain 10-50mM Tris-HCl (PH=8.1-8.5), 50mM KCl, 0.5-3.0mM NgCl 2 , 10-25mM (NH 4 ) 2 SO 4 , gelatin 200 μg/ml, 4-8% formazan, dNTP (A·G·C·T) 200-300 μM each, 1-1.5U heat-resistant DNA polymerase, 0.25-0.5 μM of αp 1 , 0.125-0.25 μM, αp 1 , 0.125-0.25 μM of αp 1 , 0.125-0.25 μM of βp 1 , 0.125-0.25 μM of βp 1 .
将上述试剂,除了耐热DNA聚合酶以外,浓缩10倍,将引物按所需浓度配好,组成试剂盒,则使用更方便。Concentrate the above reagents by 10 times except for the heat-resistant DNA polymerase, and prepare the primers according to the required concentration to form a kit, which is more convenient to use.
采用上述PCR反应试剂体系,则PCR扩增产物的电泳带清晰明亮,没有杂带,易于鉴别。Using the above-mentioned PCR reaction reagent system, the electrophoresis bands of the PCR amplification products are clear and bright without miscellaneous bands, and are easy to identify.
扩增反应时,先将反应体系混合打匀,可以高速离心30秒钟,然后在90-93℃温度下变性3-10分钟,加酶,打匀,再离心;按90-93℃-0.5-1分钟、50-60℃ 0.5-1分钟、68-72℃ 1-2分钟作30-35个循环;再在68-72℃温度下保温数分钟,取反应产物在琼脂糖凝胶板上电泳,紫外光照射下观察电泳带。使用Hybaid或FR-300PCR扩增仪或恒温水浴扩增,采用的温度和保温时间在上述范围内适当调整。During the amplification reaction, first mix the reaction system well, then centrifuge at high speed for 30 seconds, then denature at 90-93°C for 3-10 minutes, add enzyme, beat well, and then centrifuge; at 90-93°C-0.5 -1 minute, 50-60°C for 0.5-1 minute, 68-72°C for 1-2 minutes for 30-35 cycles; then keep warm at 68-72°C for several minutes, take the reaction product on the agarose gel plate Electrophoresis, observe the electrophoresis band under ultraviolet light irradiation. Use Hybaid or FR-300 PCR amplification instrument or constant temperature water bath to amplify, and adjust the temperature and incubation time appropriately within the above range.
在该扩增程序下扩增产物在电泳显示检测时泳带清晰,灵敏度高,以正常人的血红蛋白(珠蛋白)α1基因和α2基因进行PCR扩增的产物中,278bp、603bp、400bp三个基因片段的电泳带之间的距离相等,很易识别。配上本发明的扩增试剂体系和扩增程序,这三条电泳带清晰明亮,而且条带的亮度相近。Under this amplification program, the amplified product has clear swimming bands and high sensitivity when electrophoresis shows detection. The distances between the electrophoresis bands of the three gene fragments are equal and easy to identify. Coupled with the amplification reagent system and amplification program of the present invention, the three electrophoresis bands are clear and bright, and the brightness of the bands is similar.
参照βp1、βp2基因片段400bp的标准,如果受检的人血红蛋白(珠蛋白)α基因为α1基因或α2基因缺失的杂合子,则它们α1基因或α2基因片段的扩增产物电泳带的亮度仅为β基因扩增产物400bp带亮度的一半以下。Referring to the standard of 400 bp of βp 1 and βp 2 gene fragments, if the tested human hemoglobin (globin) α gene is heterozygous for the deletion of α 1 gene or α 2 gene, the amplification of their α 1 gene or α 2 gene fragment The brightness of the product electrophoresis band is only less than half of the brightness of the 400bp band of the β gene amplification product.
如受检的人血红蛋白(珠蛋白)α基因为α1基因和α2基因缺失的纯合子,则仅有β基因扩增的产物400bp带,而没有αp1和αp3、αp1和αp2扩增的278bp、603bp电泳带。α基因族的两个序列相似的α1基因和α2基因中若缺失1个α1基因或α2基因,则为杂合子,缺两个等位α基因的为纯合子。If the tested human hemoglobin (globin) α gene is homozygous for the deletion of α 1 gene and α 2 gene, there will only be a 400bp band of the amplified product of β gene, but no αp 1 and αp 3 , αp 1 and αp 2 Amplified 278bp, 603bp electrophoresis bands. If one α1 gene or α2 gene is missing in the α1 gene and α2 gene of the α gene family with similar sequences, it is a heterozygote, and the lack of two allele α genes is a homozygote.
若受检的人血红蛋白(珠蛋白)α基因缺失3个α基因,则α1基因或α2基因片断扩增产物电泳带只有一条带,其亮度为β带亮度的一半以下;If the tested human hemoglobin (globin) α gene lacks 3 α genes, the electrophoresis band of the amplified product of the α 1 gene or α 2 gene fragment has only one band, and its brightness is less than half of the brightness of the β band;
若受检的人血红蛋白(珠蛋白)α基因缺失4个α基因,那么没有α1基因和α2基因片段扩增产物电泳带。If the tested human hemoglobin (globin) α gene lacks 4 α genes, there will be no electrophoresis bands of the amplified product of α 1 gene and α 2 gene fragments.
图1是显示检测的电泳图,1是αp1和αp3扩增的Hbα1基因片段278bp,2是αp1和αp2扩增的Hbα2基因片段603bp,3是βp1和βp2扩增的Hbβ基因片段400bp。图中黑度表示电泳带的亮度,行4是φX174(RF)-HaeⅢ的电泳带,行5是血红蛋白(珠蛋白)α基因无缺失的电泳带,即正常人血红蛋白(珠蛋白)α基因检测的结果,行6是缺失一个α2基因的人血红蛋白(珠蛋白)α基因扩增后的电泳带,是α地贫2患者的检测结果,行7是缺失两个α基因(α1和α2)的DNA基因组扩增后的电泳带,这是α地贫1患者的检测结果,行8是缺失3个α基因的DNA基因组扩增后的电泳带,这是HbH病人的检测结果,行9是4个α基因都缺失的DNA基因组扩增后的电泳带,这是Bart′s水肿患者的检测结果。Figure 1 is an electropherogram showing detection, 1 is the 278 bp Hbα 1 gene fragment amplified by αp 1 and αp 3 , 2 is the 603 bp Hbα 2 gene fragment amplified by αp 1 and αp 2, and 3 is the amplification of βp 1 and βp 2 The Hbβ gene fragment is 400bp. The blackness in the figure indicates the brightness of the electrophoresis band, row 4 is the electrophoresis band of φX174(RF)-HaeⅢ, row 5 is the electrophoresis band without deletion of the hemoglobin (globin) α gene, that is, the normal human hemoglobin (globin) α gene detection The result, line 6 is the electrophoresis band after the amplification of the human hemoglobin (globin) α gene that lacks one α 2 gene, which is the detection result of α thalassemia 2 patients, and line 7 is the deletion of two α genes (α 1 and α 2 ) The amplified electrophoresis band of the DNA genome, which is the test result of α-thalassemia 1 patient, row 8 is the amplified electrophoresis band of the DNA genome missing three α genes, which is the test result of the HbH patient, row 8 9 is the amplified electrophoresis band of the DNA genome with deletion of all 4 α genes, which is the detection result of a patient with Bart's edema.
本发明的引物顺序明确,可用DNA合成仪自动合成,在本研究领域中常规易行,引物扩增的基因明确,配上本发明的扩增试剂体系、扩增程序和电泳检测,使得显示结果清晰无疑。The sequence of the primers of the present invention is clear, and can be automatically synthesized by a DNA synthesizer. It is routine and easy to perform in this research field. The gene amplified by the primers is clear. It is equipped with the amplification reagent system, amplification program and electrophoresis detection of the present invention, so that the results can be displayed. Clearly.
本发明不仅可以分别检测α1基因和α2基因是否缺失,还可以对照比较正常人的内参照标准,准确地判断受检的人血红蛋白(珠蛋白)α基因缺失是属于α1基因和α2基因还是α1基因或α2基因缺失的纯合子或杂合子。可靠地对人血红蛋白(珠蛋白)α基因缺失进行分型检测,不会发生假阳性或假阴性的失误检测。The present invention can not only detect whether the α1 gene and the α2 gene are missing, but also compare the internal reference standard of normal people to accurately determine whether the detected human hemoglobin (globin) α gene deletion belongs to the α1 gene and the α2 gene. Genes are also homozygous or heterozygous for the deletion of the α1 gene or the α2 gene. Reliably perform typing detection for the deletion of human hemoglobin (globin) alpha gene, without false positive or false negative error detection.
本发明技术配上用本技术制成的检测试剂盒,操作方便,检测结果明确,无论是科学研究还是α基因缺失分型检测都方便可靠。The technology of the invention is equipped with a detection kit made by the technology, which is convenient to operate and has clear detection results, and is convenient and reliable for both scientific research and α gene deletion typing detection.
图1是人血红蛋白(珠蛋白)α1基因和α2基因的PCR分型检测电泳图。Fig. 1 is the electropherogram of the PCR typing detection of human hemoglobin (globin) α 1 gene and α 2 gene.
图2是HbH病先征者家系的PCR基因分型检测图。Fig. 2 is a PCR genotyping detection chart of a family with a progenitor of HbH disease.
实施例:在50μl体系中,含有10mM Tris-HCl(PH=8.5),50mMKCl,2mM MgCl2,10mN(NH4)2SO4,明胶200μg/ml,甲酰胺8%,dNTP各200μM,0.25μM的αp1,0.125μM的αp2,0.125μM的αp1,0.125μM 的βp1,0.125μM的βp2,人染色体DNA约0.5μg,用30μl液蜡复盖液面。将反应体系混合打匀,高速离心30秒,恒温水浴93℃1分钟,加入DNA聚合酶1U,打匀,离心,然后恒温水浴93℃1分钟、55℃1分钟、68℃2分钟,依次进行35个循环,循环结束后再72℃保温5分钟,取20μl反应产物在1.5%琼脂糖凝胶(含0.5μg/ml EB)板上电泳,紫外光下观察电泳带。Example: In a 50μl system, containing 10mM Tris-HCl (PH=8.5), 50mM KCl, 2mM MgCl 2 , 10mN(NH 4 ) 2 SO 4 , gelatin 200μg/ml, formamide 8%, dNTP each 200μM, 0.25μM αp 1 , 0.125 μM αp 2 , 0.125 μM αp 1 , 0.125 μM βp 1 , 0.125 μM βp 2 , about 0.5 μg of human chromosomal DNA, and cover the liquid surface with 30 μl liquid wax. Mix the reaction system well, centrifuge at a high speed for 30 seconds, add 1U of DNA polymerase in a constant temperature water bath at 93°C for 1 minute, mix well, centrifuge, and then proceed in a constant temperature water bath at 93°C for 1 minute, 55°C for 1 minute, and 68°C for 2 minutes, in sequence After 35 cycles, the cycle was completed and then incubated at 72°C for 5 minutes, 20 μl of the reaction product was electrophoresed on a 1.5% agarose gel (containing 0.5 μg/ml EB), and the electrophoresis band was observed under ultraviolet light.
该受检者为HbH病先征者家系的PCR基因分型检测例,观察到的电泳带结果如图2。该图中第6行(先征者的父亲)中第2条电泳带即αp1和αp2扩增Hbα2基因片断603bp带的亮度仅为第3条β带的亮度的一半以下,可以断定父亲是α2基因缺失的杂合子,父亲患的是α地2症。第7行是先征者母亲的受检结果,可以看到第1和第2电泳带的亮度都为第3条β带的亮度的一半以下,可以断定母亲缺失α1和α2两个α基因(α1和α2均为杂合子),因而患α地1症。先征者本人的电泳条带见第8行,其α2(603bp)电泳带全无,α1(278bp)电泳带的亮度仅为β(400bp)电泳带亮度的一半以下,可断定其缺失三个α基因,患HbH症。This subject is an example of PCR genotyping detection in a family with a progenitor of HbH disease. The results of the observed electrophoresis bands are shown in Figure 2. The brightness of the second electrophoresis band in line 6 (father of the pioneer) in the figure, that is, the 603bp band of the amplified Hbα2 gene fragment of αp 1 and αp 2 , is only half of the brightness of the third β band, so it can be concluded that The father is heterozygous for the deletion of the α2 gene, and the father suffers from α2 syndrome. Line 7 is the test result of the mother of the pioneer. It can be seen that the brightness of the first and second electrophoretic bands are both less than half of the brightness of the third β band. It can be concluded that the mother is missing two α, α 1 and α 2 Gene (α 1 and α 2 are heterozygous), thus suffering from α to 1 syndrome. The electrophoretic bands of the pioneer himself are shown in row 8. There is no α 2 (603bp) electrophoretic band, and the brightness of the α 1 (278bp) electrophoretic band is only half of the brightness of the β (400bp) electrophoretic band. It can be concluded that it is missing Three α genes, suffering from HbH disease.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN92108379A CN1062018C (en) | 1992-04-14 | 1992-04-14 | Detecting technique for human haemoglobin (globin) a* gene and gene a* |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN92108379A CN1062018C (en) | 1992-04-14 | 1992-04-14 | Detecting technique for human haemoglobin (globin) a* gene and gene a* |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1065094A CN1065094A (en) | 1992-10-07 |
CN1062018C true CN1062018C (en) | 2001-02-14 |
Family
ID=4943489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92108379A Expired - Fee Related CN1062018C (en) | 1992-04-14 | 1992-04-14 | Detecting technique for human haemoglobin (globin) a* gene and gene a* |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1062018C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1063790C (en) * | 1998-09-30 | 2001-03-28 | 复旦大学 | Method for RNA circulation reverse transcription reaction |
WO2004057946A2 (en) * | 2002-12-23 | 2004-07-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. | Method for altering the content of reserve substances in plants |
CN100420943C (en) * | 2005-06-23 | 2008-09-24 | 李卫 | Method for detecting DNA intra-molecularly hybridization with known point mutation - polyacrylamide gel electrophoresis |
CN111638261B (en) * | 2020-04-17 | 2023-04-07 | 融智生物科技(青岛)有限公司 | Computing equipment, storage medium and thalassemia screening device and system |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1038309A (en) * | 1988-05-27 | 1989-12-27 | 株式会社日立制作所 | Gene tester and device thereof |
CN1059910A (en) * | 1990-08-15 | 1992-04-01 | 阿斯特拉公司 | A kind of novel method that detects pathogenic agent with dna probe |
-
1992
- 1992-04-14 CN CN92108379A patent/CN1062018C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1038309A (en) * | 1988-05-27 | 1989-12-27 | 株式会社日立制作所 | Gene tester and device thereof |
CN1059910A (en) * | 1990-08-15 | 1992-04-01 | 阿斯特拉公司 | A kind of novel method that detects pathogenic agent with dna probe |
Also Published As
Publication number | Publication date |
---|---|
CN1065094A (en) | 1992-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105506118B (en) | Primer pair, fluorescence probe, kit and method for detecting CYP2C19 Genotypings | |
JP2001514013A (en) | Method for analyzing LTC4 synthase polymorphism and use for diagnosis | |
CN103555835B (en) | Primer and probe for screening spinal muscular atrophy (SMA) genes and using method of primer and probe | |
CN106834434B (en) | Nucleic acid, kit and method for detecting COX-1, COX-2 and GPIIIa gene polymorphism | |
CN101135665B (en) | Reagent kit detecting elevated plain pneumochysis susceptibility based on mitochondria DNA T6680C mononucleotide polymorphism | |
CN1062018C (en) | Detecting technique for human haemoglobin (globin) a* gene and gene a* | |
CN111909990B (en) | Fluorescent PCR detection method for simultaneously detecting deletion mutation and point mutation of gene by single tube | |
CN111593115B (en) | Primer and probe combination and kit for multiplex real-time fluorescence PCR detection of beta-thalassemia gene mutation | |
CN110205363A (en) | Apolipoprotein E gene KASP parting detecting reagent and its method | |
CN105331623A (en) | MTB (mycobacterium tuberculosis) rpoB mutant gene and application thereof | |
CN111808937A (en) | A Bombay-like blood group FUT1 508dupT allele and its detection method and application | |
CN108517357B (en) | Kit for detecting sudden cardiac death-related SNP (single nucleotide polymorphism) on SCN5A gene related to sudden cardiac death and detection method thereof | |
CN101470095B (en) | Reagent kit for detecting plateau pneumochysis susceptibility based on mitochondria DNA G5351A mononucleotide polymorphism | |
CN101135666B (en) | Reagent kit for detecting elevated plain pneumochysis susceptibility based on mitochondria DNA C3970T mononucleotide polymorphism | |
CN101469345B (en) | Reagent kit for detecting plateau pneumochysis susceptibility based on mitochondria DNA G709A mononucleotide polymorphism | |
CN110117669B (en) | Anti-tuberculosis drug resistance detection method based on overlap extension PCR | |
US6197509B1 (en) | Method of analyzing DNA using contiguous repeats | |
Lucotte et al. | Polymerase chain reaction detection of S and Z alpha-1-antitrypsin variants by duplex PCR assay | |
CN111394437A (en) | Primer, probe and kit for human CYP2C19 gene polymorphism and application thereof | |
Wang et al. | A new assay for CCR5del32 mutation: genotyping through the number of fragments amplified | |
CN113718025B (en) | SNP kit for diabetic retinopathy gene detection based on KASP | |
CN108660198B (en) | PCR-SBT method and reagent for genotyping of platelet membrane protein CD36 antigen | |
JP2005192418A (en) | Simple detection method for specific sequences to be detected | |
CN114480615A (en) | Primer group and kit for detecting HLA-B5101 allele | |
CN118932045A (en) | A SLC10A1 allele typing detection primer and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |